These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 38161537)

  • 21. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
    Fritsch A; Meyer M; Blaustein RO; Trujillo ME; Kauh E; Roessig L; Boettcher M; Becker C
    Clin Pharmacokinet; 2024 Jun; 63(6):751-771. PubMed ID: 38916717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
    Butler J; Usman MS; Anstrom KJ; Blaustein RO; Bonaca MP; Ezekowitz JA; Freitas C; Lam CSP; Lewis EF; Lindenfeld J; McMullan CJ; Mentz RJ; O'Connor C; Rosano GMC; Saldarriaga CI; Senni M; Udelson J; Voors AA; Zannad F
    Eur J Heart Fail; 2022 Nov; 24(11):2029-2036. PubMed ID: 36250238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction.
    Falco L; Brescia B; Catapano D; Martucci ML; Valente F; Gravino R; Contaldi C; Pacileo G; Masarone D
    J Cardiovasc Dev Dis; 2023 Sep; 10(9):. PubMed ID: 37754817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
    Olivella A; Almenar-Bonet L; Moliner P; Coloma E; Martínez-Rubio A; Paz Bermejo M; Boixeda R; Cediel G; Méndez Fernández AB; Facila Rubio L
    ESC Heart Fail; 2024 Apr; 11(2):628-636. PubMed ID: 38158630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vericiguat, organic nitrates, and heart failure in African Americans.
    Ilonze OJ; Guglin M
    Int J Cardiol; 2021 Sep; 338():136-137. PubMed ID: 34157357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF).
    Xia J; Hui N; Tian L; Liang C; Zhang J; Liu J; Wang J; Ren X; Xie X; Wang K
    Biomed Pharmacother; 2022 May; 149():112894. PubMed ID: 35367763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vericiguat for Heart Failure with Reduced Ejection Fraction.
    Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A
    Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vericiguat: A New Hope for Heart Failure Patients.
    Chiles R; Al-Horani RA
    Cardiovasc Ther; 2022; 2022():1554875. PubMed ID: 36618548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Soluble guanylate cyclase: restoration of the NO-sGC-cGMP signaling pathway activity. A new opportunity in the treatment of heart failure].
    Belenkov YN; Kozhevnikova MV
    Kardiologiia; 2023 May; 63(5):68-76. PubMed ID: 37307211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week.
    Emdin M; Aimo A; Castiglione V; Vergaro G; Georgiopoulos G; Saccaro LF; Lombardi CM; Passino C; Cerbai E; Metra M; Senni M
    J Am Coll Cardiol; 2020 Oct; 76(15):1795-1807. PubMed ID: 33032741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in contemporary medical management to treat patients with heart failure.
    Velez M
    Curr Opin Cardiol; 2023 Mar; 38(2):136-142. PubMed ID: 36718623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vericiguat: A Novel Soluble Guanylate Cyclase Stimulator for Use in Patients With Heart Failure.
    Gupta R; Lin M; Maitz T; Egeler DJ; Sood A; Aronow WS; Rajeswaran Y; Ahnert AM; Vyas AV; Frishman WH; Lanier GM
    Cardiol Rev; 2023 Mar-Apr 01; 31(2):87-92. PubMed ID: 35609251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.
    Butler J; Zheng Y; Khan MS; Bonderman D; Lund LH; deFilippi CR; Blaustein RO; Ezekowitz JA; Freitas C; Hernandez AF; O'Connor CM; Voors AA; Westerhout CM; Lam CSP; Armstrong PW;
    JACC Heart Fail; 2023 May; 11(5):583-592. PubMed ID: 37137660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing Challenges and Benefits of Vericiguat in a Patient With Decompensated Heart Failure: A Case Report.
    Speranza-Sánchez M; Zavaleta E; Sancho-Zumbado S; Elizondo-Urrutia JC; Quirós-Romero A; Chaverri-Fernández J; García-Montero J; Arguedas-Chacón S
    Cureus; 2023 Oct; 15(10):e48065. PubMed ID: 38046500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry.
    Nguyen NV; Lindberg F; Benson L; Ferrannini G; Imbalzano E; Mol PGM; Dahlström U; Rosano GMC; Ezekowitz J; Butler J; Lund LH; Savarese G
    Eur J Heart Fail; 2023 Aug; 25(8):1418-1428. PubMed ID: 37323078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying the patient with heart failure to be treated with vericiguat.
    Escobar Cervantes C; Esteban Fernández A; Recio Mayoral A; Mirabet S; González Costello J; Rubio Gracia J; Núñez Villota J; González Franco Á; Bonilla Palomas JL
    Curr Med Res Opin; 2023 May; 39(5):661-669. PubMed ID: 36897009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy.
    Di Fusco SA; Alonzo A; Aimo A; Matteucci A; Intravaia RCM; Aquilani S; Cipriani M; De Luca L; Navazio A; Valente S; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    Eur Heart J Suppl; 2023 May; 25(Suppl D):D278-D286. PubMed ID: 37213802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updates in pharmacotherapy of heart failure with reduced ejection fraction.
    Espinoza C; Alkhateeb H; Siddiqui T
    Ann Transl Med; 2021 Mar; 9(6):516. PubMed ID: 33850913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
    Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
    Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.